# Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

> **NCT00623103** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 583 (actual)

## Conditions studied

- Parkinson's Disease Dementia

## Interventions

- **DRUG:** Rivastigmine capsule
- **DRUG:** Rivastigmine transdermal patch

## Key facts

- **NCT ID:** NCT00623103
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-11
- **Final completion:** —
- **Target enrollment:** 583 (ACTUAL)
- **Last updated:** 2011-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00623103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00623103, "Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00623103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*